Source Pravda.Ru

GlaxoSmithKline plans to cut prices for HIV drugs in developing countries

GlaxoSmithKline plc (LSE: GSK NYSE: GSK), a British based pharmaceutical, biological, and healthcare company, announced Wednesday its decision to cut down the cost of HIV drugs in developing countries.

The most significant decrease (almost 40% price reduction) will affect its antiretroviral Ziagen.

Ziagen, the trade name for Abacavir (ABC) is a nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS. It has been well tolerated: the main side effect is hypersensitivity, which can be severe and, rarely, fatal. Genetic testing can indicate whether an individual will be hypersensitive; over 90% of patients can safely take abacavir. After the price reduction it will cost about $15 per pack, or about 50 cents daily.

The company is also going to reduce prices for Lexiva by 20% to $3.35 daily. Lexiva is a pro-drug of the protease inhibitor and antiretroviral drug amprenavir.

Actually the reduction is possible due to improved manufacturing and less expensive raw ingredients used to produce the drugs.

The US is going to ban exports of Iranian oil to the world market from November 5 of this year. In turn, Iran threatens to block the passage of oil tankers of the Gulf countries through the Strait of Hormuz

Will Iran close the Strait of Hormuz to trigger global oil crisis?

The US is going to ban exports of Iranian oil to the world market from November 5 of this year. In turn, Iran threatens to block the passage of oil tankers of the Gulf countries through the Strait of Hormuz

Will Iran close the Strait of Hormuz to trigger global oil crisis?

The World Cup that is about to finish in Russia has shown that the Western propaganda machine has failed to create the image of Russia as a monster with "many tentacles." By and large, the Russians and the Ukrainians are close to each other

Putin-Trump meeting to decide the future of Ukraine